Summary

Ecnoglutide (also known as XW003) is a long-acting, biased GLP-1 receptor agonist developed by Sciwind Pharmaceuticals. Unlike conventional GLP-1 agonists, ecnoglutide is designed to preferentially activate G-protein signalling pathways over β-arrestin recruitment, which may offer improved efficacy and tolerability. Phase 3 trial results published in 2025 demonstrated significant weight loss in adults with overweight or obesity. It is not currently licensed in the UK.

Mechanism

Ecnoglutide is a biased GLP-1 receptor agonist. It preferentially activates the G-protein signalling pathway (cAMP/PKA) at the GLP-1 receptor while showing reduced β-arrestin recruitment compared to unbiased agonists like semaglutide. This biased signalling profile is hypothesised to sustain receptor activity (less desensitisation/internalisation) and may reduce gastrointestinal side effects. The net effect is enhanced insulin secretion in a glucose-dependent manner, suppression of glucagon, delayed gastric emptying, and increased satiety — consistent with GLP-1 receptor pharmacology.

Evidence base

A Phase 3 randomised, double-blind, placebo-controlled, multicentre trial published in The Lancet Diabetes & Endocrinology (2025) demonstrated statistically significant weight loss with ecnoglutide in adults with overweight or obesity. This is the first Phase 3 readout for the compound. Evidence grade: Moderate. The trial supports ecnoglutide's efficacy as a GLP-1 RA, but head-to-head comparisons with approved agents and long-term cardiovascular outcomes data are not yet available.

Protocols

In Phase 3 trials, ecnoglutide was administered as a once-weekly subcutaneous injection with a dose-titration schedule. Specific dose levels have not been prominently disclosed in publicly available topline results. As an investigational compound, no approved dosing guidelines exist.

Ecnoglutide is not licensed by the MHRA and is not approved as a medicine in the UK. It is an investigational peptide in the grey area — legal for research purposes but not available as an approved therapeutic. The MHRA has not evaluated ecnoglutide for safety, quality, or efficacy.

Vendor notes

Ecnoglutide is an investigational compound not in legitimate commercial distribution. No UK vendors are vetted. Any vendor claiming to sell ecnoglutide should be treated with extreme caution.

References

  1. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology, 2025. DOI: 10.1016/S2213-8587(25)00141-X
  2. ClinicalTrials.gov search results for ecnoglutide. Available at: https://clinicaltrials.gov/search?term=ecnoglutide